Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 18F-Fluciclovine PET/CT in a case series of 10 patients with prostate cancer recurrence

Purpose: This is a head-to-head comparison between Gallium-68 Prostate Specific Membrane Antigen (68Ga-PSMA-11) and 18F-Fluciclovine Positron Emission Tomography/Computed Tomography (PET/CT) in a series of 10 patients with prostate cancer (PCa) recurrence.

Methods: 288 patients with PCa recurrence were enrolled in a prospective study of 68Ga-PSMA-11 PET/CT imaging for recurrent disease localization (NCT02940262). We retrospectively identified 10 patients who underwent clinical indicated 18F-Fluciclovine PET/CT prior enrollment. Results: The median time between both scans was 2.3 months (range 0.2-4.2). The median PSA value was 1.0 ng/ml (mean 4.7 ng/ml; range 0.13-18.1) and 1.1 ng/ml (mean 6.2 ng/ml; range 0.24-31.3) at the time of 18F-Fluciclovine and 68Ga-PSMA-11 PET/CT, respectively. 5/10 patients (50%) were negative on 18F-Fluciclovine PET/CT but showed positive results on 68Ga-PSMA-11 PET/CT. 2/10 patients (20%) had both positive 18F-Fluciclovine and 68Ga-PSMA-11 PET/CT but 68Ga-PSMA-11 PET/CT showed additional lymph nodes (LN) metastasis. 3/10 patients (30%) had both negative 18F-Fluciclovine and 68Ga-PSMA-11 PET/CT. Conclusion: This case series suggests superior detection rate of 68Ga-PSMA-11 PET/CT than 18F-Fluciclovine PET/CT in recurrent PCa. Prospective trials designed to directly compare 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT should be initiated.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2017 Dec 14 [Epub ahead of print]

Jeremie Calais, Wolfgang P Fendler, Ken Herrmann, Matthias Eiber, Francesco Ceci

UCLA, United States.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe